Podcasts about medicines

Last week, startling headlines hit the news. Three commonly prescribed medicines, hydrochlorothiazide, used to treat high blood pressure, voriconazole, an antifungal medicine and tacrolimus, an immunosuppressant were classified as carcinogenic, or cancer causing, to humans. The classification was made by the International Agency for Research on Cancer or IARC, which is the World Health Organization's cancer research agency.According to the IARC, there is sufficient evidence that hydrochlorothiazide causes squamous cell carcinoma of the skin and cancer of the lip, as the drug makes the skin more sensitive to ultraviolet radiation. Voriconazole, also has been linked to the same cancers. In the case of Tacrolimus since it suppresses the immune system to prevent rejection of transplanted organs, the reduced immune surveillance may allow abnormal cells to proliferate and it is linked with non-Hodgkin lymphoma with limited evidence for other cancers as well.These drugs are prescribed to millions of people worldwide. So what happens now? Guest: Dr. Rajeev Jayadevan convener, research cell, Kerala State IMA and honorary senior consultant gastroenterologist, Sunrise Hospital, Kochi. Host: Zubeda Hamid Edited by Sharmada Venkatasubramanian Learn more about your ad choices. Visit megaphone.fm/adchoices

Pharmaceuticals Made in South Africa (Pharmisa) is calling for urgent government intervention to combat the illicit trade in medicines, warning that the illegal market now also involves healthcare practitioners. Pharmisa Chairperson Stavros Nicolaou made the call during a presentation to Parliament's Standing Committee on Trade, Industry and Competition, which is this week receiving stakeholder submissions on South Africa's Industrial Development Strategy.

We could really use some healing after last episode's nightmare, so along comes the medic fantasy manga The Beast King: Master of Medicines! And good news, it's better than the last series we did about a healer. But will this story of demon and human working together to cure monsters and save the world be the tonic we so desperately need? ~ Welcome to That Time I Started A Podcast To Read Trash Manga With My Friends And Actually Most Of Them Were Trash But Some Of Them Weren't! Or The Trash Manga Friends Podcast, for short. The trash journey never ends! Every fortnight our trio of hosts, Sean, Mike and Phil, pick out a manga, webtoon, manhua or manhwa, read the first two volumes (or equivalent), and then spend the next hour or so having an existential breakdown about it. Some are good! Some are bad. Most are trash. So join us, for our seventh year, as we slowly close in on 200 episodes and series covered! ~ Follow us on social media! Links to all platforms on our site - https://trashmangafriends.carrd.co/ Sean, your, say it with us, foooreeeeveeeer host, can be found on Bluesky & Twitch - https://bsky.app/profile/slazo.bsky.social ~ https://www.twitch.tv/slazoking Mike, your streamer haternaire, can be found everywhere @Bersekrer - https://bersekrer.carrd.co/ Phil, your master of trashimonies, can't be found on Twitter @PheNaxKian - https://twitter.com/PheNaxKian ~ Support the official release! The Beast King: Master of Medicines is licensed by Seven Seas Entertainment - https://sevenseasentertainment.com/series/the-beast-king-master-of-medicines/

Jason Coloma, CEO of South San Francisco-based Maze Therapeutics, on developing small molecule drugs based on human genetics for kidney diseases.

Cada vez mais pessoas têm contato com o uso de Ayahuasca e dos famosos "cogumelos mágicos". Mas pouco se sabe sobre os impactos que essas substâncias têm na nossa saúde. O que a ciência sabe, hoje, sobre isso? Confira o papo entre o leigo curioso, Ken Fujioka, e o cientista PhD, Altay de Souza. >> OUÇA (57min 07s) * SOBRE O NARUHODO Naruhodo! (@naruhodopodcast) é o podcast pra quem tem fome de aprender. Ciência, senso comum, curiosidades, desafios e muito mais. Com o leigo curioso, Ken Fujioka (@kenfujioka), e o cientista PhD, Altay de Souza (@altayals). Edição: Reginaldo Cursino (@reginaldocursino) Ilustração e Capa: Felipe Cruz (@felipecruzart) http://naruhodo.b9.com.br * REFERÊNCIAS Psychedelics as Medicines for Substance Abuse Rehabilitation: Evaluating Treatments with LSD, Peyote, Ibogaine and Ayahuasca https://www.ingentaconnect.com/content/ben/cdar/2014/00000007/00000002/art00005 A Systematic Review on the Therapeutic Effects of Ayahuasca https://www.mdpi.com/2223-7747/12/13/2573 Ayahuasca Treatment Outcome Project (ATOP): One-Year Results from Takiwasi Center and Implications for Psychedelic Science https://www.jsad.com/doi/abs/10.15288/jsad.23-00005 Ayahuasca-assisted meaning reconstruction therapy for grief: a non-randomized clinical trial protocol https://www.frontiersin.org/journals/psychiatry/articles/10.3389/fpsyt.2024.1484736/full The Future of the Biopsychosocial Model: Toward a Transdisciplinary Systems Science of Mental Health  https://media.eiko-fried.com/publications/2026-robinaugh-clinical-psychological-science-the-future-of-the-biopsychosocial-model.pdf Lopes, Inês Magalhães (2017). Do Kamo, Ser-no-mundo e a Universalização da Concepção Individualista de Pessoa (PDF). Lisboa: Instituto Universitário de Lisboa, Escola de Ciências Sociais e Humanas The Legacy of Maurice Leenhardt https://journals.sagepub.com/doi/10.1177/239693938901300408 Ayahuasca and the traveller: A scoping review of risks and possible benefits https://www.sciencedirect.com/science/article/abs/pii/S1477893921002477 Mental Disorders as Homeostatic Property Clusters A Narrative Review  https://media.eiko-fried.com/publications/2026-fried-jama-psychiatry-mental-disorders-as-homeostatic-property-clusters-a-narrative-review.pdf Revisiting the theoretical and methodological foundations of depression measurement  https://media.eiko-fried.com/publications/2022-fried-nature-reviews-psychology-revisiting-the-theoretical-and-methodological-foundations-of-depression-mea.pdf Reassessing the cultural and psychopharmacological significance of Banisteriopsis caapi: preparation, classification and use among the Piaroa of Southern Venezuela https://pubmed.ncbi.nlm.nih.gov/19004422/ Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: a randomized placebo-controlled trial https://pmc.ncbi.nlm.nih.gov/articles/PMC6378413/ The Psychedelic Future of Post-Traumatic Stress Disorder Treatment https://www.benthamdirect.com/content/journals/cn/10.2174/1570159X22666231027111147 Risk of bias in randomized clinical trials on psychedelic medicine: A systematic review https://journals.sagepub.com/doi/full/10.1177/02698811231180276 How to set up a psychedelic study: Unique considerations for research involving human participants https://www.sciencedirect.com/science/article/pii/S0149763426001144 Psycholytic Therapy Using LSD: a Realist Review https://onlinelibrary.wiley.com/doi/full/10.1002/brb3.71187 Safety and Efficacy of Repeated Low-Dose LSD for ADHD Treatment in Adults https://jamanetwork.com/journals/jamapsychiatry/fullarticle/2831639 Preliminary Findings on Low-Dose 1cp-LSD for Canine Anxiety: Exploring the Role of Owner Neuroticism and Psychopathology https://www.mdpi.com/2306-7381/12/9/872 Efficacy and Safety of LSD in the treatment of mental and substance use disorders: A systematic review of randomized controlled trials https://www.sciencedirect.com/science/article/abs/pii/S0165178125002707 Evaluating the Impact of a Low Dose of LSD on EEG Spectral Signature in Participants with Depressed Mood (Abstract ID: 163720) https://jpet.aspetjournals.org/article/S0022-3565(24)42708-0/fulltext Efficacy and safety of low- versus high-dose-LSD-assisted therapy in patients with major depression: A randomized trial https://www.cell.com/med/fulltext/S2666-6340(25)00152-7 Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: a randomized placebo-controlled trial  https://repositorio.ufrn.br/server/api/core/bitstreams/79cb4dd8-9bca-4b4a-832b-b6940029b65b/content Naruhodo #266 - Por que vemos luzes quando fechamos os olhos?  https://www.youtube.com/watch?v=3_4r_ZGb4wA Naruhodo #220 - Existe causa para a depressão? - Parte 1 de 2  https://www.youtube.com/watch?v=cFo8GFwyuR0 Naruhodo #221 - Existe causa para a depressão? - Parte 2 de 2  https://www.youtube.com/watch?v=5peXBmG43lU Naruhodo #419 - Maconha faz mal? - Parte 1 de 2  https://www.youtube.com/watch?v=cvLTh2bKPiQ Naruhodo #420 - Maconha faz mal? - Parte 2 de 2  https://www.youtube.com/watch?v=F7wVcGvpoGA Naruhodo #106 - Hipnose funciona? - Parte 1 de 2  https://www.youtube.com/watch?v=XIHUilfmAzQ Naruhodo #107 - Hipnose funciona? - Parte 2 de 2  https://www.youtube.com/watch?v=O42Yo2zt5vs Naruhodo #461 - O que é a teoria da Incompletude de Godel?  https://www.youtube.com/watch?v=XQRu2ogFvMQ * APOIE O NARUHODO! O Altay e eu temos duas mensagens pra você. A primeira é: muito, muito obrigado pela sua audiência. Sem ela, o Naruhodo sequer teria sentido de existir. Você nos ajuda demais não só quando ouve, mas também quando espalha episódios para familiares, amigos - e, por que não?, inimigos. A segunda mensagem é: existe uma outra forma de apoiar o Naruhodo, a ciência e o pensamento científico - apoiando financeiramente o nosso projeto de podcast semanal independente, que só descansa no recesso do fim de ano. Manter o Naruhodo tem custos e despesas: servidores, domínio, pesquisa, produção, edição, atendimento, tempo... Enfim, muitas coisas para cobrir - e, algumas delas, em dólar. A gente sabe que nem todo mundo pode apoiar financeiramente. E tá tudo bem. Tente mandar um episódio para alguém que você conhece e acha que vai gostar. A gente sabe que alguns podem, mas não mensalmente. E tá tudo bem também. Você pode apoiar quando puder e cancelar quando quiser.  O apoio mínimo é de 15 reais e pode ser feito pela plataforma ORELO ou pela plataforma APOIA-SE. Para quem está fora do Brasil, temos até a plataforma PATREON. É isso, gente. Estamos enfrentando um momento importante e você pode ajudar a combater o negacionismo e manter a chama da ciência acesa. Então, fica aqui o nosso convite: apóie o Naruhodo como puder. bit.ly/naruhodo-no-orelo

DR PAM KRYSKOW is the medical lead for the Roots To Thrive Program. She is actively involved in research related to psilocybin, MDMA, ketamine and front line health care workers and first responders’ mental wellness. She is co-investigator on the largest microdosing study Microdose.me. Home

https://rumble.com/user/TheCultureWarshttps://x.com/NewsK365https://buymeacoffee.com/courtpresshttps://www.youtube.com/@NewsK365Email: newsk365@protonmail.com

https://rumble.com/user/TheCultureWarshttps://x.com/NewsK365https://buymeacoffee.com/courtpresshttps://www.youtube.com/@NewsK365Email: newsk365@protonmail.com

https://rumble.com/user/TheCultureWarshttps://x.com/NewsK365https://buymeacoffee.com/courtpresshttps://www.youtube.com/@NewsK365Email: newsk365@protonmail.com

https://rumble.com/user/TheCultureWarshttps://x.com/NewsK365https://buymeacoffee.com/courtpresshttps://www.youtube.com/@NewsK365Email: newsk365@protonmail.com

https://rumble.com/user/TheCultureWarshttps://x.com/NewsK365https://buymeacoffee.com/courtpresshttps://www.youtube.com/@NewsK365Email: newsk365@protonmail.com

Every Wednesday afternoon, we'll be talking Making Babies.Andrea will be joined by Professor Shane Higgins, Consultant Obstetrician and Gynaecologist, to cover every area of trying to have a baby. From the very start of knowing how to prepare, right up to pregnancy – and all the bumps in the road in between.This week, Shane joins Andrea to discuss everything you need to know about taking medicines during pregnancy.

Host Ben Plumley speaks with Solange Baptiste Simon and Othoman Mellouk of the International Treatment Preparedness Coalition (ITPC) about their packed treatment pre-conference and concerns that treatment is being sidelined amid heavy focus on PrEP and prevention. They argue the prevention-versus-treatment framing is false, emphasizing a continuum from testing to prevention to treatment, and describe on-the-ground chaos as HIV services are integrated into broader chronic care with overstretched health workers and communities. They discuss a “strange” AIDS 2026 marked by funding cuts and reduced PEPFAR influence, uneven country leadership, and a shift from scientific innovation to challenges of financing, manufacturing, regulation, and equitable delivery of long-acting technologies. They caution against product-driven responses, stress human rights and stigma realities, and conclude that community power, involvement, and resourcing remain central to sustainable solutions. 00:00 Welcome and Guests 01:08 Treatment Preconference Highlights 03:13 Prevention vs Treatment Debate 05:00 Continuum of Care Reality 07:34 Clinic Integration Chaos 10:07 Conference Avoiding Hard Truths 14:58 Post PEPFAR Future 18:39 Product Hype vs Access 22:58 Fiscal Space and Priorities 25:13 Beyond Biomedical Fixes 30:19 2030 Targets Reality Check 32:29 Crossroads and Policy Choices 36:15 Community Hope and Closing 38:23 Final Thanks and Signoff Guests: Solange Baptiste Simon Executive Director, ITPC Othoman Mellouk Access to Medicines & Diagnostic Lead, ITPC ITPC Global https://itpcglobal.org AIDS 2026 https://www.iasociety.org/conferences/aids2026 Check Out Ben's Substack: https://substack.com/@benplumley1 Join the Conversation! How do you see the future of global health unfolding? Share your thoughts in the comments! Subscribe & Stay Updated: Listen on Spotify, Apple Podcasts, or your favorite podcast platform. Watch on YouTube & subscribe for more in-depth global health. #hivaids #HIV #AIDS #globalhealth #AIDS2026 #ITPC

What happens when a 16-year Google veteran (who also worked at Microsoft) decides to fix drug discovery with AI?You get Pauling AI, a next-generation molecular simulation platform built to discover the medicines of tomorrow.In this episode of Game of Pharma, Javier, CEO & Founder of Pauling AI and Ex-Technical Director at Google Healthcare & Life Sciences, shares his journey from leading Search, Ads, Supply Chain, and Cloud at Google (with prior experience at Microsoft) to building AI tools that could shape the future of pharmaceutical research.What you'll learn in this episode:→ Why Javier left Google after 16 years to bet on biotech AI→ What's actually working in AI drug discovery (vs the hype)→ Why biotech startups adopt AI faster than Big Pharma→ How Pauling AI is reimagining molecular simulation→ The next 5 years of AI in pharmaIf you're curious about where AI meets drug discovery, this conversation is unmissable.️ Listen on Spotify: https://open.spotify.com/show/4EDgDoe...️ Apple Podcasts: https://podcasts.apple.com/us/podcast...Subscribe to our newsletter: https://game-of-pharma.beehiiv.com---ABOUT JAVIER:Javier is a technology executive, and entrepreneur. Currently leading Pauling AI, a next-generation molecular simulation platform.Previously: 16 years at Google (Search, Ads, Supply Chain, Cloud). Prior experience at Microsoft and McKinsey.Education: Superior Engineer in Computer Science, Masters in Mathematics (Dropped out of Ph.D. in Mathematics to pursue building software.)ABOUT GAME OF PHARMA:World's leading pharma podcast with 25,000+ subscribers globally. Featuring conversations with the brightest minds in pharmaceuticals.Website: https://gameofpharma.com/LinkedIn:  / game-of-pharma-podcast  

Ever been curious about psychedelics? If so, you're not alone. But consuming psychedelic plant medicines has always been taboo, even when it comes to healing modalities. Over the years, more research has shown that plant medicines, when taken with intention, can have a positive impact on one's psyche and healing journey. Katherine Petrullo is the founder of Lüminate and creator of Women of Impact. Her work weaves together Taoist philosophy, tantra, kundalini, and plant medicine. Before her success, she was a young woman quietly falling apart, cycling through rock bottoms, and reaching for anything external that might make her feel whole, a feeling she had never truly known. Katherine explains what finally shifted, including a plant medicine ceremony, and what she learned on the other side of it. Click 'play' to see if psychedelics might be your next (unexpected) healing modality.What You Will Learn[00:07:30] Childhood existential anxiety — and distorting her voice to feel safe[00:13:30] Why plant medicine wasn't the magic bullet she expected[00:17:00] Why not feeling safe to share kept her deeply isolated[00:30:30] What her first ayahuasca ceremony actually felt like — and the dark night of the soul that followed[00:36:00] What coming back into the body actually felt like[00:46:00] How the medicine wheel explains why so many people experience energy crashes and empty creation[00:53:30] What Women of Impact is — and what it's actually designed to do[01:01:00] Why healing isn't something you're always doing — it's a danceResources MentionedMany Lives, Many Masters by Brian WeissLet's Connect!Katherine PetrulloWebsite | InstagramChandler StroudWebsite | LinkedIn | InstagramHappiness Academy is now Healing Heroines, a signature space for women who are ready to feel more grounded, more peaceful, and more aligned — inside and out. Download a complimentary Healing Roadmap to discover our Past, Present, and Possible framework.Want personalized guidance for your healing journey? Book a call with Chandler!Mixing and editing provided by Next Day Podcast.Text message us questions, requests, or comments!

Lyn Baranowski, CEO of Boston-based Avalyn Pharma, on developing inhalable medicines for severe lung diseases.

China's high-tech sectors are gaining global traction, with surgical robot exports jumping 330% in the first half as AI, robotics and innovative medicines emerge as new pillars of growth.

Dr. Cristine Hull is an integrative mental health practitioner, author, and developer of the Zero Point Meridian technique. With a Master's in Psychology and a Ph.D. in Natural Medicine, she brings over two decades of experience as a substance abuse counselor, school psychologist, and private practitioner. Drawing from her own journey through depression, anxiety, addiction, and a profound spiritual awakening, Cristine works at the intersection of brain chemistry, energy medicine, and the quantum field. She is the creator of the Four Bodies model and trains practitioners in tools that address the physical, vital, mental, and quantum levels of healing. Based in northern Utah, she continues to teach, write, and guide people toward deeper wholeness through her work at Health, Healing & Wholeness.In this episode, Cristine and I cover a wide-ranging conversation that moves from brain chemistry and addiction into spiritual awakening, energy medicine, and what real healing actually requires.Cristine shares her personal journey through severe depression, anxiety, and substance use, and how those experiences led her into decades of work as a counselor and integrative practitioner. She introduces her Four Bodies model (physical, vital, mental, and quantum) and explains why most lasting change has to address more than just the physical level. The conversation explores sugar as part of the narcotic continuum, the difference between dopamine and endorphin addiction, the spiral of recovery she developed while teaching in a jail, and the powerful spiritual experience she had on Yom Kippur that shifted everything. We also dig into entities and generational energy, the development of her Zero Point Meridian technique, the “neutral game” for quieting the mental body, and why conventional mental health often falls short with personality disorders and chronic pain. Cristine closes by pointing back to the deeper truth underneath the endorphin chase: capital-L Love.Timestamps0:00 – Elevator pitch / “junkyard love” framing and four bodies intro1:30 – Four Bodies for Medicines ebook and physical vs. vital/mental/quantum3:00 – Wind analogy for spirit/effects on the physical body4:30 – Personal history: chemical imbalance, depression, anxiety, substances6:30 – First career in substance-abuse counseling; self-medication insight8:00 – Serotonin, carbs, Potatoes Not Prozac, wheat sensitivity discovery9:30 – Endorphins as “inner orphan” / morphine parallel; sugar as narcotic continuum11:00 – Dopamine vs. endorphins; cocaine, bipolar diagnosis, mastering the middle path13:00 – Love addiction, romantic craving, spiral model (abstinence → moderation → attainment)15:00 – Jail curriculum development; 20 years clean vs. relationship patterns still unresolved16:30 – Yom Kippur night/boyfriend breakup; Day of Atonement context18:00 – Light shaft experience through the crown/spine; “whole and complete through divine connection”19:30 – Kundalini as vital-body tool (chakras, meridians, aura)21:00 – Growing up Christian, leaving religion, seeking freedom from guilt and pain22:30 – Cocaine phase; friend returning from overdose funeral; entity/attachment theory24:30 – “Perverse energy” (Quantum University language); generational clearing26:00 – First Kundalini session clearing grandfather's heavy emotion27:30 – EFT training (2002–2003, Gary Craig); shift to private practice29:00 – Zero Point Meridian (ZPM) development; claimed superiority data vs. EMDR31:00 – Mental body chaos of positive/negative thinking; neutrality / “neutral game”34:00 – Yoga entry via client accountability + Baron Baptiste Journey into Power36:00 – Gap between stimulus and response; mind-body necessity of yoga37:30 – TM interest; Vipassana documentary (Doing Time, Doing Vipassana)39:00 – Mahasati movement meditation; fear that stillness = non-existence / black hole41:00 – Moving through zero; zero-point field → unified field; John Hagelin / Frank Kinslow52:00 – Limits of conventional mental health on personality disorders (narcissism, borderline, ego structures)54:00 – Spiritual/quantum solution as transformative where pills and talk therapy fall short56:00 – Quantum Solutions Masterclass / ego-structure component57:30 – Chronic pain and the pain body (Eckhart Tolle); noticing pain-free body parts as anchors59:00 – Endorphins at quantum level = capital-L Love; closing gratitudeKEYWORDS:Four bodies model, Zero Point Meridian, ZPM technique, quantum body, vital body, endorphin continuum, sugar addiction recovery, love addiction spiral, attainment model, perverse energy, generational clearing, Yom Kippur awakening, Kundalini vital body, neutral game mindfulness, Quantum Wholeness Meditation, Love Solve Method, Frequency Formulas, personality disorder spiritual solution, pain body Eckhart Tolle, brain chemistry natural balance, EFT to ZPM evolution, Cache Valley healer, integrative mental health Utah.Checkout more Cristine here! :Website: Cristine HullYoutube - Health, Healing, & Wholeness - YouTubeInstagram - Author Cristine Hull (@cristine.author)LinkedIn - Cristine Hull PhD LinkedinFaceBook - Author Cristine Hull • FacebookQuotes from Cristine in the episode:“Love is an answer. It's a solution for sure.”“The wind is actually the spirit. The effects are the physical body.”“Endorphins… stands for inner orphan, which like morphine… highly addictive… sugar.”“The trick was not to try to change it and stay up. The trick was to realize when I was down, there was some work to do…”“Really, all that matters is that you are whole and complete through a divine connection. And you bring your whole self to it.”“I believe the person who overdosed came with her and walked through the door… this entity… attached to me.”“If we try to use the mind to correct the mind, we can get just a lot of chaos… the solution… is neutrality.”“There's not a lot in mental health and psychology to solve personality disorders… the problem is because there's not really a spiritual solution in the mental health field.”“Notice where you're not in pain - tune into even if it's your hair… their hair doesn't hurt, the tip of their nose probably doesn't hurt…”“What people are looking for in the endorphin experience is love. And it's a capital L-O-V-E…”If you enjoyed our conversation - please like, subscribe, and we'll see ya next on the next episode!

Patients wating for life-changing medicines to be funded say people should not have to fundraise, got into debt or travel overseas for treatments and therapies that could be administered here. The Forbidden Pharmacy at Auckland's Shed 10 is an installation showing shelves of medicines locked behind doors, representing what people may need but can't access because they are not funded by Pharmac. Amy Williams reports.

The Forbidden Pharmacy is an art pop-up in Auckland's Shed 10 that took place on Friday, July 24. In the installation there are over 200 medicines that are currently unfunded in New Zealand but needed by patients. "The literal cost of living here is what it costs patients to either live, extend their life, or live well," Forbidden Pharmacy Spokesperson Ah-Leen Rayner told Heather du Plessis-Allan. "What we know is that an increase of 0.1% of GDP would clear the backlog, and that's of the medicines that Pharmac would like to fund if they had the money today. And that still leaves us investing only a third of what other developed nations spend on medicine access." LISTEN ABOVE See omnystudio.com/listener for privacy information.

Mental health remains one of medicine's greatest unmet needs. In this episode, Jacob Hooker explains how Sensorium Therapeutics is searching for new psychiatric medicines by combining traditional plant knowledge with cutting-edge drug development. Jacob joins Rafael Rosengarten to discuss how centuries of ethnobotanical knowledge, modern AI, and medicinal chemistry are helping uncover new treatments for anxiety, epilepsy, and cognitive disorders. Along the way, they explore the science behind psychoactive plants, the growing global burden of mental health conditions, and what the future of psychiatric medicine could look like if researchers can move beyond symptom management toward lasting brain health.TPM E59 highlights >⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Episode 59 links:Sensorium Therapeutics Aether in Mind SubstackBook recommendationsRichard Evans Schultes: Plants of the GodsMark J. Plotkin: Tales of a Shaman's Apprentice Wade Davis: One River The Plants of the Gods podcastUpdated trends in the global prevalence and burden of mental disorders, 1990–2023: a systematic analysis for the Global Burden of Disease Study 2023Americans for Ibogaine

The rise of weight loss jabs could completely change the way people shop, and not just for food, according to a leading business consultancy. A new report by EY looks at the way GLP1 weight loss medicines are influencing consumer choices in Australia and what that could mean for business. Report co-author, Lisa Nijssen-Smith spoke to Lisa Owen.

Fluent Fiction - Hindi: A Moment of Misplaced Medicines: Trust and Hope Restored Find the full episode transcript, vocabulary words, and more:fluentfiction.com/hi/episode/2026-07-16-07-38-19-hi Story Transcript:Hi: गर्मियों का दिन था।En: It was a summer day.Hi: सूरज की तेज़ किरणें फ़ील्ड अस्पताल के ऊपर जल रही थीं।En: The intense rays of the sun were blazing over the field hospital.Hi: यह एक अस्थायी अस्पताल था, जिसमें तंबू लगे हुए थे और लोग बैचैन होकर इधर-उधर भागते नज़र आते थे।En: This was a temporary hospital, with tents set up, and people were seen anxiously running around.Hi: फ़ील्ड के किनारे खड़ा, डॉक्टर आरव एक खाली डिब्बे को देख रहा था।En: Standing at the edge of the field, Dr. Arav was looking at an empty box.Hi: उसकी आँखों में चिंता साफ़ झलक रही थी।En: Worry was clearly reflected in his eyes.Hi: अस्पताल में मरीजों की भीड़ बढ़ रही थी, और अचानक आयी हीटवेव के कारण हालात और गंभीर होते जा रहे थे।En: The crowd of patients in the hospital was increasing, and due to the sudden heatwave, the situation was becoming more serious.Hi: आरव ने गहरी सांस ली और मेहरा के पास गया।En: Arav took a deep breath and went to Mehra.Hi: मेहरा एक दयालु नर्स थी, जिसके चेहरे पर हमेशा मुस्कान रहती थी।En: Mehra was a kind nurse, who always had a smile on her face.Hi: वो आरव के प्रति अपने प्यार को गुप्त रखती थी, परंतु हर समय उसका सहयोग करती थी।En: She kept her love for Arav secret, but she always supported him.Hi: "मेहरा, दवाइयाँ गायब हैं," आरव ने चिंतित स्वर में कहा।En: "Mehra, the medicines are missing," Arav said in a concerned voice.Hi: "हमें यह समस्या हल करनी होगी।En: "We need to solve this problem."Hi: "मेहरा ने सहमति में सिर हिलाया, "हां, आरव।En: Mehra nodded in agreement, "Yes, Arav.Hi: हम किसी को भी इसे पता नहीं चलने देंगे।En: We won't let anyone find out about this."Hi: "इस बीच, राज ने, जो एक नया इंटर्न था, उनकी चर्चा सुनी।En: Meanwhile, Raj, who was a new intern, overheard their conversation.Hi: राज भले ही अनुभवहीन था, लेकिन उसकी आँखों में कुछ होशियारी झलकती थी।En: Although Raj was inexperienced, there was a certain cleverness in his eyes.Hi: वह भी इस गुप्त जांच का हिस्सा बनना चाहता था।En: He also wanted to be a part of this secret investigation.Hi: आरव ने पूरी योजना सुनायी।En: Arav explained the entire plan.Hi: सबको कमरा तटोलने और सबूत इकठ्ठा करने के लिए कहा गया।En: Everyone was told to search the room and gather evidence.Hi: रात होते ही अस्पताल शांत हो गया।En: As night fell, the hospital became quiet.Hi: पर आरव, मेहरा और राज चुपचाप अपनी योजना पर काम करते रहे।En: But Arav, Mehra, and Raj quietly continued to work on their plan.Hi: मेहरा ने अस्पताल की पर्चियाँ जांचीं, जबकि राज ने भंडारण कक्ष में चारों ओर देखा।En: Mehra checked the hospital sheets, while Raj looked around in the storage room.Hi: अचानक, राज के मुंह से एक हल्की सी चीख निकल गयी।En: Suddenly, a soft scream escaped from Raj.Hi: उसने एक कोने में कुछ बक्से छुपे देखे।En: He saw some boxes hidden in a corner.Hi: आरव और मेहरा जल्द ही वहां पहुँचे।En: Arav and Mehra quickly arrived there.Hi: आरव ने बक्से खोलना शुरू किया और पाया कि सभी दवाइयाँ उन्हीं में थीं।En: Arav started opening the boxes and found that all the medicines were in them.Hi: "राज!En: "Raj!Hi: ये कैसे हुआ?En: How did this happen?"Hi: " आरव ने थोड़ा कड़वे स्वर में पूछा।En: Arav asked in a slightly bitter tone.Hi: राज ने थोड़ी शर्मिंदगी में सिर झुका लिया।En: Raj hung his head in a bit of embarrassment.Hi: "सॉरी सर, मुझे लगा कि दवाइयाँ चोरी हो सकती हैं।En: "Sorry, sir, I thought the medicines might be stolen.Hi: इसलिए मैंने इन्हें यहाँ छिपा दिया।En: So, I hid them here."Hi: "आरव थोड़ी देर तक चुप रहे, फिर हँस पड़े।En: Arav remained silent for a while, then burst out laughing.Hi: "राज, मैं तुम्हारे इरादे समझ सकता हूँ, पर हमें जिम्मेदारी और समझदारी से काम करना होगा।En: "Raj, I can understand your intentions, but we have to work with responsibility and understanding."Hi: "वाकया समाप्त होने पर आरव ने धैर्य और समझदारी से राज के काम को सराहा और उसे सिखाया कि कैसे टीम के साथ विश्वास कायम रखना चाहिए।En: At the conclusion of the incident, Arav patiently and understandingly appreciated Raj's work and taught him how to build trust with the team.Hi: इस घटना ने न केवल आरव को अपने सहयोगियों के प्रति और सहनशील बनाया, बल्कि राज को भी समझदारी और परिपक्वता सिखाई।En: This incident not only made Arav more tolerant toward his colleagues but also taught Raj wisdom and maturity.Hi: जब सूरज की नई किरणें अस्पताल के तंबूओं पर पड़ीं, तो वहां उम्मीद की एक नई रोशनी थी।En: When the new rays of the sun fell on the hospital's tents, there was a new light of hope there. Vocabulary Words:intense: तेज़rays: किरणेंblazing: जल रहीtemporary: अस्थायीanxiously: बैचैनedge: किनारेreflected: झलक रहीsudden: अचानकheatwave: हीटवेवserious: गंभीरconcerned: चिंतितintern: इंटर्नcleverness: होशियारीinvestigation: जांचevidence: सबूतstorage: भंडारणembarrassment: शर्मिंदगीintentions: इरादेresponsibility: जिम्मेदारीunderstanding: समझदारीtrust: विश्वासconclusion: वाकया समाप्तtolerant: सहनशीलcolleagues: सहयोगियोंwisdom: समझदारीmaturity: परिपक्वताsecret: गुप्तnodded: सहमति में सिर हिलायाapologetic: माफ़ी मांगने वालाappreciated: सराहा

Stephen Grootes speaks to Ruaan Louw, Managing Director of iDexis, about the company's decision to appeal a recent High Court judgment and regulatory findings relating to its compounding of GLP-1 and GIP medicines. iDexis maintains that its products were safe, says independent testing found no evidence of sterility failures, and argues that regulators were aware of its compounding activities long before the dispute reached court. The Money Show is a podcast hosted by well-known journalist and radio presenter, Stephen Grootes. He explores the latest economic trends, business developments, investment opportunities, and personal finance strategies. Each episode features engaging conversations with top newsmakers, industry experts, financial advisors, entrepreneurs, and politicians, offering you thought-provoking insights to navigate the ever-changing financial landscape.    Thank you for listening to a podcast from The Money Show Listen live Primedia+ weekdays from 18:00 and 20:00 (SA Time) to The Money Show with Stephen Grootes broadcast on 702 https://buff.ly/gk3y0Kj and CapeTalk https://buff.ly/NnFM3Nk For more from the show, go to https://buff.ly/7QpH0jY or find all the catch-up podcasts here https://buff.ly/PlhvUVe Subscribe to The Money Show Daily Newsletter and the Weekly Business Wrap here https://buff.ly/v5mfetc The Money Show is brought to you by Absa     Follow us on social media   702 on Facebook: https://www.facebook.com/TalkRadio702 702 on TikTok: https://www.tiktok.com/@talkradio702 702 on Instagram: https://www.instagram.com/talkradio702/ 702 on X: https://x.com/CapeTalk 702 on YouTube: https://www.youtube.com/@radio702   CapeTalk on Facebook: https://www.facebook.com/CapeTalk CapeTalk on TikTok: https://www.tiktok.com/@capetalk CapeTalk on Instagram: https://www.instagram.com/ CapeTalk on X: https://x.com/Radio702 CapeTalk on YouTube: https://www.youtube.com/@CapeTalk567 See omnystudio.com/listener for privacy information.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a series of significant advancements and challenges shaping the landscape of these dynamic sectors. Starting with Ipsen's Dysport, which has made notable strides in its Phase 3 trials for migraine prevention. The trials covered both episodic and chronic conditions, marking a first in the neurotoxin market. Dysport's success positions it as a formidable competitor to AbbVie's Botox, expanding therapeutic options for individuals battling migraine disorders. This achievement showcases the potential efficacy of botulinum toxin-based therapies in neurology and pain management, offering promising new avenues for patient care. In regulatory news, Boehringer Ingelheim has received approval from the Medicines and Healthcare products Regulatory Agency (MHRA) for Jascayd, a small molecule PDE4B inhibitor with antifibrotic properties. This approval marks a significant milestone in the treatment of idiopathic and progressive pulmonary fibrosis. Jascayd's addition to the therapeutic arsenal offers new hope for managing this debilitating condition, emphasizing the ongoing efforts to improve patient outcomes through innovative treatments. The arena of business development sees HanChorBio partnering with InxMed to advance oncology research. By combining HCB101 with FAK inhibitors and FAP-targeted ADCs, this collaboration aims to leverage antibody and small molecule drug discovery techniques. The goal is to develop innovative cancer treatments that could redefine therapeutic approaches in oncology. Keenova Therapeutics has also reported success with Xiaflex for plantar fibromatosis. This enzyme injection therapy offers a novel approach by targeting collagen, thus providing an innovative solution for musculoskeletal conditions. Similarly, Fate Therapeutics' FT819, an off-the-shelf CAR-T therapy, has shown early promise in tackling treatment-resistant systemic sclerosis, underscoring the potential of cell therapies beyond oncology. Meanwhile, MindRank's successful Series B funding round of $52 million highlights the growing role of AI platforms in drug discovery. The funding will propel its AI-discovered oral GLP-1 obesity pill into Phase III trials, exemplifying how technology-driven solutions are gaining traction in addressing metabolic diseases like obesity. On the regulatory front, Saol Therapeutics has resubmitted SL1009 (DCA) to the FDA for pyruvate dehydrogenase complex deficiency. This submission underscores ongoing efforts to address rare metabolic disorders using small molecule therapies. Additionally, Sanofi's concessions to the EU regarding flu vaccine marketing illustrate the complexities of competitive dynamics and regulatory scrutiny within the vaccine market. However, not all developments are favorable. AstraZeneca and Ionis Pharmaceuticals faced a setback as their drug Wainua failed its Phase 3 trial for transthyretin-mediated amyloid cardiomyopathy. This outcome highlights the challenges inherent in developing effective treatments for complex cardiovascular conditions. Meanwhile, regulatory processes remain contentious as the FDA pauses its release of complete response letters amid debates over proprietary information disclosures. In another noteworthy development, GSK has terminated its $2.2 billion collaboration with Alector after underwhelming results from Alzheimer's drug trials. This decision highlights both financial implications and strategic shifts as companies reassess risk tolerance in neurodegenerative disease research. Conversely, Roche's success with its KRAS G12C inhibitor divarasib in Phase 3 lung cancer trials underscores the promise of precision medicine. Divarasib outperformed competitors Amgen's Lumakras and Bristol Myers Squibb's Krazati, positioning Roche to potentially redefine standards of care based on genetic profiles. In a move reflecting industry trends towards collaboration and innovation risk-sharing models, AstraZeneca has partnered with Sino Biopharmaceutical on respiratory disease research. This strategic alliance represents a substantial investment aimed at expanding AstraZeneca's pipeline in respiratory therapeutics. Lastly, amidst these developments, psychedelic drugs are experiencing a renaissance in psychiatric care. Companies like Compass Pathways are pioneering clinical validation for their use in treating depression, signaling a potential paradigm shift from traditional SSRIs to newer therapeutic classes pending safety and efficacy data. Overall, these stories illustrate a dynamic interplay of scientific progress and regulatory navigation within the pharmaceutical and biotech sectors. While challenges persist—particularly in neurodegenerative disease treatment—the breakthroughs in oncology and metabolic disorder therapeutics offer hopeful prospects for improving patient care. As these industries continue evolving, integrating advanced technologies such as AI will likely play a pivotal role in shaping future therapeutic landscapes.Support the show

India is often called the ‘pharmacy of the world' — it exports one-fifth of the world's generic medicines and meets over half of the global vaccines demand. Yet when it comes to discovering the next breakthrough medicine, India's contribution remains surprisingly small.----more----Read full article here: https://theprint.in/feature/india-manufacturing-medicines-discovering-funding-key/2973560/

Clinical trial support companies are rapidly adopting AI, but sponsors have been more hesitant. Raj Indupuri, CEO of eClinical Solutions, gives the top three reasons behind the holdup in AI agent deployment. He explains the specific pattern of uptake for these agents, the required human-in-the-loop oversight, and how the agents can improve clinical trial velocity. Host Deborah Borfitz also gives the latest news on a highly acclaimed treatment for pancreatic cancer, filling evidence gaps in drug safety during pregnancy, guidelines for routinely collected health data for research purposes, an innovative portal aiding bidirectional communication with patients, and more. Show Notes News Roundup KRAS inhibitor therapy for pancreatic cancer Study in The New England Journal of Medicine  News on the Fred Hutch Cancer Center website  Target trial emulation in rural areas Perspective in the Medical Journal of Australia News on the Griffith University website   AI for improving drug safety during pregnancy Report from the Journal of Medical Internet Research Guidelines on the use of routinely collected data Article in The BMJ New regulatory framework in the U.K. Press release by the Medicines and Healthcare products Regulatory Agency  Participant Engagement Portal Article in JNCI Cancer Spectrum Press release from the Alliance for Clinical Trials in Oncology The Scope of Things podcast explores clinical research and its possibilities, promise, and pitfalls. Clinical Research News senior writer, Deborah Borfitz, welcomes guests who are visionaries closest to the topics, but who can still see past their piece of the puzzle. Focusing on game-changing trends and out-of-the-box operational approaches in the clinical research field, the Scope of Things podcast is your no-nonsense, insider's look at clinical research today.  

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. The first quarter of 2026 has brought a wave of significant changes and advancements in the industry, marked by crucial regulatory updates, strategic acquisitions, and shifts in the competitive landscape. A pressing issue for many companies is the looming patent cliff for several branded biologics. This situation presents both challenges and opportunities for biosimilars in the U.S. market. The introduction of biosimilars for major products like AbbVie's Humira, Johnson & Johnson's Stelara, and Regeneron/Bayer's Eylea is shifting the narrative from slow adoption to a more competitive biosimilar market landscape. Vertex Pharmaceuticals has achieved a milestone with the FDA expanding the label for its gene therapy Casgevy, now approved for treating children as young as two with sickle cell disease or transfusion-dependent beta thalassemia. This expansion emphasizes the potential of gene therapies to revolutionize treatment options for younger patients suffering from these conditions. In a pivotal development, Novartis announced a significant acquisition of UK biotech Myricx. With an upfront payment of $1.1 billion and potential total value up to $1.5 billion, this acquisition is set to enhance Novartis' antibody-drug conjugate (ADC) pipeline by incorporating Myricx's novel payload technology and NMT inhibitor payloads. This move reflects Novartis' focus on precision oncology by improving ADC efficacy through targeting critical enzymatic pathways involved in tumorigenesis. Amgen faced a setback with a voluntary recall of approximately one million bottles of its heart medication Corlanor due to potential contamination, highlighting the critical importance of maintaining rigorous manufacturing quality control to ensure drug safety. The regulatory landscape continues to evolve, illustrated by Robert F. Kennedy Jr.'s Department of Health and Human Services revoking lingering COVID-19 emergency authorizations. This signals a transition towards post-pandemic normalcy and an evolving focus on pandemic preparedness frameworks. Sanofi's Genzyme unit in Ireland faced criticism after an FDA inspection linked to Altuviiio resulted in a Form 483 notice. This incident underscores ongoing challenges in maintaining compliance with stringent regulatory standards and emphasizes the importance of robust quality assurance mechanisms. Lonza is expanding its capacity for producing ADCs and enhancing its partnership with a large U.S. drugmaker, aligning with industry trends toward outsourcing complex biologics manufacturing amid growing demand for ADCs. Genentech is undergoing restructuring, resulting in 103 layoffs as part of a strategic rethink of its early development group. Despite these changes, Genentech entered a $490 million collaboration focused on breast cancer, demonstrating its commitment to innovation amid organizational shifts. AstraZeneca continued its collaborative efforts by signing a $1.7 billion kidney drug discovery pact with Chinese biotech CSPC Pharmaceutical. This partnership emphasizes AstraZeneca's strategy to leverage global collaborations to accelerate drug discovery and development efforts. Scribe Therapeutics filed for an Initial Public Offering (IPO) to advance its CRISPR-based gene editing technologies targeting cardiovascular diseases at a genetic level, highlighting an ongoing shift toward personalized medicine. Celea Therapeutics raised $180 million in venture funding to advance Deupirfenidone into late-stage clinical trials for Idiopathic Pulmonary Fibrosis (IPF), signaling confidence in its therapeutic potential amid ongoing investment trends targeting rare diseases. The Medicines and Healthcare products Regulatory Agency expanded approval for Novo Nordisk's Wegovy for Metabolic-Associated Steatohepatitis with moderate-to-advanced liver fibrosis. This expansion represents significant progress given MASH's rising prevalence and progression risks. BridgeBio's ATTRibute-CM study yielded promising results with Acoramidis offering kidney-protective benefits in transthyretin amyloidosis cardiomyopathy patients—a potential new approach managing this rare disease. Revolution Medicines reported encouraging data for its KRAS inhibitor Zoldonrasib in combination therapies targeting metastatic pancreatic ductal adenocarcinoma—offering new strategies against aggressive cancer types. Brii Bio's phase 2b trial results show promise for a combination therapy aimed at achieving a functional cure for chronic Hepatitis B Virus infection—offering hope for millions affected by this condition. Robust fundraising activities continue within biotech sectors as Monash University and Atisama Therapeutics secure funding from MRFF grants developing therapies targeting chronic lung diseases. Overall, these developments highlight dynamic transformations reshaping therapeutic landscapes through precision medicine approaches leveraging cutting-edge technologies promising improved patient care across various domains within pharmaceutical industries globally.Support the show

Americans pay roughly three times as much for prescription meds as people in other wealthy nations. But why? Tahir Amin argues it's largely to do with how our patent systems work. He's been on both sides of the issue: He spent a decade as an intellectual property lawyer, helping corporations use patents to protect their bottom lines. Then he moved to India and saw firsthand how the global patent system hampered access to HIV drugs. That led him to shift gears and create an advocacy organization aimed at changing the patent system to make access to medicines more equitable. He chats with Flora about how it all works, and his new book, “Pharma Monopoly.” Read an excerpt from “Pharma Monopoly: The Battle for the Future of Medicines.” Guest: Tahir Amin is a co-author of “Pharma Monopoly: The Battle for the Future of Medicines” and a founder and CEO of Initiatives for Medicine Access and Knowledge (I-MAK).  Transcripts for each episode are available within 1-3 days at sciencefriday.com. Subscribe to this podcast. Follow our show on Instagram, TikTok, Facebook, and Bluesky @scifri and sign up for our newsletters. Got a science question that's keeping you up at night? Call us: 877-472-4374 Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

For the last episode in the second series of Magic and Medicines, we're talking about Palmistry and Phrenology!We start by looking at uses of palmistry across the world, from Vedic astrology with Hindu Jyotish over to the divination practices of the Chinese Ming dynasty.We discuss whether or not it's true that Aristotle discovered an ancient palmistry text and got Alexander the Great into the art, and explore the stereotypes associated with fortune telling in general, and some nasty xenophobic history.Then, we have a look at our own hands, and try and work out whether we've got 'fire hands' or 'air hands', and what the lines in our palms say about us.In the third part of the episode, we look at the concept of phrenology, from its roots as possible brain science through to its manipulation and abuse by proponents of eugenics, and its alarming similarity to the work done by some algorithms today...We really hope you enjoy the episode, and we will speak to you again on Thursday with a new tale from the Red Fairy Book, Minnikin!Three Ravens is an English Myth and Folklore podcast hosted by award-winning writers Martin Vaux and Eleanor Conlon.Released on Mondays, each weekly episode focuses on one of England's 39 historic counties, exploring the history, folklore and traditions of the area, from ghosts and mermaids to mythical monsters, half-forgotten heroes, bloody legends, and much, much more. Then, and most importantly, the pair take turns to tell a new version of an ancient story from that county - all before discussing what that tale might mean, where it might have come from, and the truths it reveals about England's hidden past...Bonus Episodes are released on Thursdays plus Local Legends episodes on Saturdays - interviews with acclaimed authors, folklorists, podcasters and historians with unique perspectives on that week's county.With a range of exclusive content on Patreon, too, including audio ghost tours, the Three Ravens Newsletter, and monthly Three Ravens Film Club episodes about folk horror films from across the decades, why not join us around the campfire and listen in?REGISTER FOR THE TALES OF SOUTHERN ENGLAND TOURVisit our website Join our Patreon Social media channels and sponsors Hosted on Acast. See acast.com/privacy for more information.

REPLAY: "For the Love of" Our Sacred Medicines Join us in re-listening to this special episode with Robin Wall Kimmerer, award winning author, citizen of the Potawatomi Nation, mother, scholar, scientist, and a giver of knowledge. Auntie Lisa opens this special episode with a new introduction, reflecting on our time spent with Robin! Originally part of our "For the Love of" series in February, this episode is centered on our sacred medicines as the Aunties dive deep into conversation with Robin, highlighting the love and abundance mother earth provides. Please sit back, enjoy and take in the lessons that Robin is so talented in sharing with us!  Wabanaki Words Used: Apc-oc (again in the future, parting, good-bye, farewell) - https://pmportal.org/dictionary/apc-oc   Topics Discussed:   Robin Wall Kimmerer - https://www.robinwallkimmerer.com/ “Braiding Sweetgrass” by Robin Wall Kimmerer - https://bookshop.org/p/books/braiding-sweetgrass-indigenous-wisdom-scientific-knowledge-and-the-teachings-of-plants-robin-wall-kimmerer/6fa4d296293d20e8?ean=9781571313560&next=t Carlisle Indian School - https://www.npca.org/parks/carlisle-federal-indian-boarding-school-national-monument “The Serviceberry” by Robin Wall Kimmerer - https://bookshop.org/p/books/the-serviceberry-abundance-and-reciprocity-in-the-natural-world-robin-wall-kimmerer/11103aae5b752d02?aid=86677&ean=9781668072240&listref=robin-wall-kimmerer&next=t “The First Blade of Sweetgrass” by Suzanne Greenlaw and Gabriel Frey - https://www.amazon.com/First-Blade-Sweetgrass-Suzanne-Greenlaw/dp/0884487601 Monique Smith - https://wordfest.com/artist/monique-gray-smith/ “Bud Finds Her Gift” by Robin Wall Kimmerer - https://bookshop.org/p/books/bud-finds-her-gift-robin-wall-kimmerer/615a02894e9290a1?aid=86677&ean=9780063324428&listref=robin-wall-kimmerer&next=t The Briar Patch - https://briarpatchbooks.square.site/ Plant Baby Plant - https://plantbabyplant.com/   Wabanaki Tribal Nations: Houlton Band of Maliseet Houlton Band of Maliseet Indians | Littleton, ME (maliseets.net) Mi'kmaq Mi'kmaq Nation | Presque Isle, ME (micmac-nsn.gov) Passamaquoddy Tribe Indian Township Passamaquoddy Tribe @ Indian Township | Peskotomuhkati Motahkomikuk Passamaquoddy Tribe Sipayik Sipayik Tribal Government – Sipayik (wabanaki.com) Penobscot Nation Penobscot Nation | Departments & Info | Indian Island, Maine   Special Thanks/Woliwon:  Guest: Robin Wall Kimmerer Producer: Gavin Allen Podcast Team: Macy Flanders

Episode Summary Tahir Amin started out wanting to play professional football in England. He found law instead, and specifically intellectual property law in the early 1990s, when the field was still new enough to feel cutting edge. After a decade of commercial IP practice in the UK and the US, he moved to India in 2004 to understand what the new global IP rules were doing to the people they never accounted for. He arrived just as India was being required to comply with WTO patent rules that would affect access to HIV medicines costing tens of thousands of dollars a year. That experience led him to co-found I-MAK in 2006. In this conversation, Amin walks Rubino through the political economy of drug patents: how neoliberal policy from the late 1970s onward handed control of publicly funded research to private companies, how those companies built out sprawling patent portfolios to delay generic competition, and how the word "innovation" became a shield against any real scrutiny. He also talks about what I-MAK's work has achieved, the blowback it has faced, and why he considers himself a "cynical optimist" who believes the long game is the only game worth playing. Key Takeaways Patent stacking is the norm, not the exception. Novo Nordisk filed more than 320 patent applications around the single active ingredient in the Ozempic family of drugs. 1 in 3 Americans are skipping doses or cutting pills to afford their medications. This is a policy problem rooted in decisions made over the past four decades. The word "innovation" replaced "invention" deliberately around 1976–77, allowing corporations to privatize public-funded knowledge and charge rent for it. I-MAK's public patent database puts the evidence on the table. The pharma industry attacks the messenger rather than engaging the data. Incrementalism is the system's release valve. Real change requires playing the long game, not chasing the next quick win. Links & Resources Above the Law The Jabot Podcast Tahir Amin at I-MAK Pharma Monopoly: The Battle for the Future of Medicines by Tahir Amin (book) Keywords pharmaceutical patents, drug pricing, patent monopoly, medicine access, IP law, I-MAK, Tahir Amin, patent stacking, Ozempic patents, Novo Nordisk, innovation myth, neoliberalism, affordable medicine, generic drugs, biosimilars, patent reform, WTO patent law, drug affordability, pharma policy, Jabot podcast Episode Highlights 00:08:18 - 00:09:16 Amin explains the founding of I-MAC and the need to challenge systems treating public knowledge as monopoly property. 00:12:49 - 00:13:33 The survey data: 1 in 3 Americans are skipping or rationing medications, a Western problem as much as a global one. 00:16:12 - 00:16:55 Novo Nordisk's 320+ patent applications on the Ozempic active ingredient, and how that data changed the Congressional conversation. 00:21:52 - 00:24:54 The linguistic shift from "invention" to "innovation" after the late 1970s, and why the distinction matters for policy. 00:30:27 - 00:31:32 Why incrementalism is the system's release valve, and the case for committing to real, structural change over the long run.  

Every year, the counterfeit pharmaceutical market generates up to $400 billion — dwarfing the global street drug trade. But the danger isn't just financial. Fake medicines may contain no active ingredients, toxic contaminants, or unregulated chemicals — and most people have no idea they're taking them. In this episode of The Index, we speak with Oksana Pyzik, Associate Professor at UCL School of Pharmacy and founder of its Fight the Fakes Collaborating Centre, about the growing threat of counterfeit pharmaceuticals: who's buying them, who's producing them, and why criminal networks are increasingly choosing fake medicines over street drugs.

New Zealanders are waiting almost twice as other countries to get modern medicines. US pharmaceutical research shows New Zealand's processes for registering, approving and funding modern medicines are the slowest out of 20 OECD countries. Medicine NZ chief executive Graeme Jarvis says other countries have similar wealth ratings and size - so we can't blame being poor and small. "You want to give patients the access now, because if they wait too long, they become the ambulance at the bottom of the cliff and the rest of the health system, which is over-worked as it is, is having to deal with the patients in the interim." LISTEN ABOVESee omnystudio.com/listener for privacy information.

Kelly sits down with Dr. Jeremy Levin, Executive Chairman and founder of Ovid Therapeutics, a public company focused on medicines for epilepsies and seizure-related brain disorders. He has a fantastic new book titled “Biotech in the Balance: Saving a Strategic Industry in an Age of Distrust.”  “Misinformation spreads faster than corrections.”  “Talented people learn that candor carries risk.”  “Medicines […]

Professor Michael Barry, Director of the NCPE.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a series of compelling advancements and strategic maneuvers transforming the industry landscape. Intellia Therapeutics has made remarkable progress with lonvoguran ziclumeran, achieving an 89% reduction in attack rates in its Phase 3 trial for hereditary angioedema. This gene therapy utilizes CRISPR technology combined with antisense oligonucleotides, highlighting the transformative potential of genetic editing techniques. The success of this approach underscores CRISPR's promise in offering long-term solutions through single-dose treatments, setting a benchmark for future therapies targeting genetic disorders. Regulatory dynamics are also shifting, as evidenced by Germany's move to abandon its variable drug discount plans after major pharmaceutical companies like Boehringer Ingelheim and Eli Lilly withdrew investments. This decision highlights the ongoing complexities and challenges in drug pricing policies, which are vital for maintaining equitable access to medications while ensuring economic sustainability for pharmaceutical companies. On the manufacturing front, Recipharm is investing significantly to upgrade its U.S. production capabilities in response to rising demand for biologics. This trend reflects an industry-wide push towards expanding biologic drug manufacturing infrastructure, driven by biologics' potential for personalized medicine applications. Similarly, Eisai has secured a UK government grant to expand its Hatfield plant for monoclonal antibody production, while Johnson & Johnson is investing $1 billion to enhance Acuvue contact lens production. These expansions illustrate how major companies are bolstering manufacturing capabilities to support strategic growth and meet increasing product demand. Merck & Co.'s partnership with Protillion Biosciences, valued at $510 million, exemplifies the growing integration of AI/ML technology in drug discovery. This collaboration aims to leverage Protillion's Prot-map protein design platform to enhance data generation and accelerate biologics development, illustrating how artificial intelligence is streamlining drug discovery processes. In clinical trials, promising developments continue to emerge. Spyre Therapeutics reported that SPY002 met its Phase 2 primary endpoint in ulcerative colitis with anti-TL1A results, positioning it as a potential leader in autoimmune disease therapies. Edgewise Therapeutics also presented supportive Phase 2 data for EDG-7500, which targets hypertrophic cardiomyopathy, paving the way for Phase 3 trials. These advancements highlight the potential of small molecules and combination therapies in addressing complex diseases. Additionally, Alto Neuroscience's ALTO-207 has shown benefits for anhedonia in major depressive disorder patients through independent Phase 2 data. This underscores ongoing progress in treating neurological disorders using innovative combinations of established compounds like dopamine agonists and ondansetron. The landscape is further enriched by Moderna's expansion plans. Anticipating up to three new product launches between 2027 and 2028, Moderna is restructuring its operations under new leadership. This strategic realignment aims to streamline processes across commercial, manufacturing, and R&D divisions ahead of significant product launches. Regulatory collaboration is advancing, with the FDA and UK's Medicines and Healthcare products Regulatory Agency (MHRA) initiating a new liaison program. This initiative aims to harmonize regulatory responses across borders, potentially accelerating drug approvals.Support the show

Scientists have made a new scientific breakthrough in the study of the human body.Researchers in the United States have discovered something amazing: a third circulatory system within the human body.Alongside the previously known cardiovascular and lymphatic systems, this interstitium system (as it's being called) appears to allow the different organs of the human body to pass things along to one another.Which in-and-of-itself is an amazing discovery, but it's made even more exciting by the fact that this newly discovered system maps very well onto the model of the human body that's been used in traditional Eastern medicine for thousands of years (in practices like acupuncture, for instance).Meaning, this discovery might very well be the missing link between Western and Eastern medicine.Let's go through the details together.

In this episode, I'm joined by global health advocate, founder and CEO of the Initiative for Medicines, Access, and Knowledge (I-MAK), and author Tahir Amin to discuss his groundbreaking book Pharma Monopoly: The Battle for the Future of Medicines. Drawing on decades of work challenging pharmaceutical patents and advocating for equitable access to medicine, Amin argues that the modern drug system is shaped not only by science, but by law, politics, economics, and monopoly power. From insulin and cancer drugs to the lessons of the COVID-19 pandemic, this conversation explores who controls medicine, who profits from it, and what a more just global health system could look like.

We're growling, purring and hissing our way into this month's Magic and Medicines episode to talk all about Familiars and Animal Magic!We start by talking about animistic beliefs in early societies, along with associations of animals with particular deities, before diving into Medieval and Renaissance ideas about witches' familiars documented in witch trial materials.With Vinegar Tom, Sacke-and-Sugar and Pecke-in-the-Crowne frolicking about our feet, we explore beliefs about how familiars might be summoned - and whether or not they are really something far more sinister than a magical companion. There's a bit of Jungian psychology, of course, and an eclectic selection of beliefs from around the world - but are appearances of animals within spiritual practices really just symbols to assist us with self-development?Moving into the 21st century, we discuss neo-shamanism, power animals, and how domestic pets can be spiritually comforting to practitioners of magic and spirituality today, before rounding out the conversation by looking to the future with digital familiars and AI companions!We really hope you enjoy the episode, and we will speak to you again on Thursday with The Golden Branch, a longer Lang tale!Three Ravens is an English Myth and Folklore podcast hosted by award-winning writers Martin Vaux and Eleanor Conlon.Released on Mondays, each weekly episode focuses on one of England's 39 historic counties, exploring the history, folklore and traditions of the area, from ghosts and mermaids to mythical monsters, half-forgotten heroes, bloody legends, and much, much more. Then, and most importantly, the pair take turns to tell a new version of an ancient story from that county - all before discussing what that tale might mean, where it might have come from, and the truths it reveals about England's hidden past...Bonus Episodes are released on Thursdays plus Local Legends episodes on Saturdays - interviews with acclaimed authors, folklorists, podcasters and historians with unique perspectives on that week's county.With a range of exclusive content on Patreon, too, including audio ghost tours, the Three Ravens Newsletter, and monthly Three Ravens Film Club episodes about folk horror films from across the decades, why not join us around the campfire and listen in?REGISTER FOR THE TALES OF SOUTHERN ENGLAND TOURVisit our website Join our Patreon Social media channels and sponsors Hosted on Acast. See acast.com/privacy for more information.

John Maytham is joined by Dr Lindiwe Gumede, Senior Lecturer and Head of the Department of Medical Imaging and Radiation Sciences at the University of Johannesburg, whose research explores why these conversations are not happening and how bridging the gap between traditional and Western medicine could ultimately save lives. Presenter John Maytham is an actor and author-turned-talk radio veteran and seasoned journalist. His show serves a round-up of local and international news coupled with the latest in business, sport, traffic and weather. The host’s eclectic interests mean the program often surprises the audience with intriguing book reviews and inspiring interviews profiling artists. A daily highlight is Rapid Fire, just after 5:30pm. CapeTalk fans call in, to stump the presenter with their general knowledge questions. Another firm favourite is the humorous Thursday crossing with award-winning journalist Rebecca Davis, called “Plan B”. Thank you for listening to a podcast from Afternoon Drive with John Maytham Listen live on Primedia+ weekdays from 15:00 and 18:00 (SA Time) to Afternoon Drive with John Maytham broadcast on CapeTalk https://buff.ly/NnFM3Nk For more from the show go to https://buff.ly/BSFy4Cn or find all the catch-up podcasts here https://buff.ly/n8nWt4x Subscribe to the CapeTalk Daily and Weekly Newsletters https://buff.ly/sbvVZD5 Follow us on social media: CapeTalk on Facebook: https://www.facebook.com/CapeTalk CapeTalk on TikTok: https://www.tiktok.com/@capetalk CapeTalk on Instagram: https://www.instagram.com/ CapeTalk on X: https://x.com/CapeTalk CapeTalk on YouTube: https://www.youtube.com/@CapeTalk567 See omnystudio.com/listener for privacy information.

Paramedics will be authorised to prescribe medicines in a move aimed at reducing pressure on emergency departments. Hato Hone St John deputy chief executive of clinical services, Jon Moores spoke to Ingrid Hipkiss.

Welcome to a warm summer's evening in a Medieval barn, complete with twilight birdsong, for Three Ravens Live @ Chiltern Open Air Museum!Set across 45 acres of the Chiltern Hills, "COAM" rescues endangered historic buildings and reconstructs them at its picturesque site - one where a working historic farm and traditional craftspeople continue Buckinghamshire's old folk occupations and ensure they live on in the modern day. Learn more here.This recording, made last Saturday evening, is a celebration of not just COAM and the Chiltern Hills but the entire county of 'Bucks' - a place once ruled over by the pagan king Cymbeline, through which Woden dug a very big ditch, and where Little Witches might hypnotize your sheep before hippy-hopping away over the nearest hedgerow...From the county's ancient gold and silver mints at Aylesbury to the furniture makers of High Wycombe - at least two of whom stuck around after death - local delicacies including the Buckinghamshire Bacon Badger to Augustinian monks catching devils in their shoes, Bucks might not have a particular reputation for being folky, but that's only because the county's people have been keeping quiet about it! Including performances of traditional folk songs Green Bushes and The Barley Mow by Ben and Eleanor, and Eleanor's haunting live performance of local folktale A Promise Kept with dramatic live underscoring, it's an evening to remember, interrupted by a pigeon and topped off with a Q&A session with our lovely live audience!We really hope you enjoy it, and will speak to you again on Monday for the penultimate episode of our Bonus Series Magic and Medicines, all about Familiars and Animal Magic!P.S. We recorded a whole second episode after the audience went home, during which we explored the museum's historic buildings and searched for ghosts between midnight and 2am. We still have work to do to edit it all together, but that decidedly spooky recording will be coming out on the Three Ravens Patreon during July!Three Ravens is an English myth and folklore podcast hosted by Eleanor Conlon and Martin Vaux.Released on Mondays, each weekly episode focuses on one of England or Wales' 39 historic counties, exploring the history, folklore and traditions of the area, from ghosts and mermaids to mythical monsters, half-forgotten heroes, bloody legends, and much, much more. Then, and most importantly, the pair take turns to tell a new version of a traditional story from that county - all before discussing what that tale might mean, where it might have come from, and the truths it reveals about England's hidden past...Bonus Episodes are released on Thursdays plus Local Legends episodes - interviews with acclaimed authors, folklorists, podcasters and historians with unique perspectives on that week's county - and Live Shows come out on Saturdays.With a range of exclusive content on Patreon too, including audio ghost tours, the Three Ravens Newsletter, and monthly Three Ravens Film Club episodes about folk horror films from across the decades, why not join us around the campfire and listen in?REGISTER FOR THE TALES OF SOUTHERN ENGLAND TOURVisit our website Join our Patreon Social media channels and sponsors Hosted on Acast. See acast.com/privacy for more information.

The CEO of Kalshi joins to discuss the company's latest product announcements and the regulatory environment for prediction markets. Then, Former Defense Secretary Mark Esper helps break down the latest headlines on the war with Iran. We also speak with the CEO of D-Wave Quantum following the U.S. government's recent investment in quantum companies. Plus, the CEO of Revolution Medicines joins to discuss the company's pancreatic cancer drug that nearly doubled survival rates.   Squawk on the Street Disclaimer Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

A new book examines the how pharmaceutical corporations set high drug prices and what can be done about it.

While many St. Louisans are celebrating signs of the start of summer, heat-related illnesses can put a damper on summertime fun — and can lead to serious harm. In this encore episode, clinical assistant professor and community pharmacist Catherine Gilmore joins St. Louis on the Air to discuss the science behind what happens to the body when it fails to regulate heat and how certain types of medication can increase the risk of heat intolerance.

Dr. Spencer Nadolsky and Karl sit down with Dr. Susan Brian, a Yale-trained endocrinologist, certified menopause provider, and medical director of a clinic with seven endocrinologists who runs an active bone fragility fracture clinic, to answer the question that has been flooding social media since a viral abstract with two fake bones on a surgical table convinced people their skeletons are quietly dissolving.Follow Dr. Susan here In this episode they cover why the preclinical and mechanistic data on GLP-1 medicines actually points toward bone benefit rather than harm by improving osteoblast activity and reducing osteoclast activity, why the meta-analyses from over two decades of GLP-1 use in type 2 diabetes show reduced fracture risk rather than increased risk, what the recent Israeli retrospective cohort study actually found and why an 11% increased fragility fracture signal in older adults on GLP-1 for diabetes versus other treatments deserves attention without panic, why almost every nutritional deficiency flagged in GLP-1 patients turns out to be vitamin D deficiency that likely predated the medicine, why the degree of weight loss matters far more than the medicine itself and how the one to two pounds per week threshold and the one percent of body weight per week guideline translate into real clinical practice, what the Hansen JAMA 2024 study showed about GLP-1 alone versus GLP-1 with resistance training and why that finding is the single most important takeaway for anyone on these medicines, why Spencer has idiopathic hypercalciuria and was spilling 650 milligrams of calcium per day in his urine before anyone caught it, how romosozumab works and why it is the most powerful bone building medicine available, why Dr. Brian orders baseline bone densities on patients well before the standard screening age and why insurance almost always covers it, and why comparing GLP-1 nutritional risk to bariatric surgery nutritional risk is not even close to an apples to apples comparison. The Docs Who Lift podcast distills and simplifies the complexities of exercise, medicine, and weight loss. Subscribe so you never miss an episode. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.